Targeting triple negative breast cancer: Is p53 the answer?

Natalie Turner, Erica Moretti, Olimpia Siclari, Ilenia Migliaccio, Libero Santarpia, Maurizio D'Incalci, Stefano Piccolo, Andrea Veronesi, Alberto Zambelli, Gianni Del Sal, Angelo Di Leo

Research output: Contribution to journalArticle

73 Citations (Scopus)

Abstract

Triple negative breast cancers, which are defined by lack of expression of estrogen, progesterone, or HER2 receptors, represent approximately 15% of all breast cancers, although they account for a much higher proportional of breast cancer mortality. This is due both to their innate aggressive biological characteristics, but also to lack of effective therapies. Conventional chemotherapy is currently the only treatment option, thus there is a critical need to find new and effective targeted therapies in this disease. While investigation of agents such as poly (ADP-ribose) polymerase (PARP) inhibitors and EGFR inhibitors continues, results from recent clinical trials indicate that these therapies are not as active in sporadic triple negative breast cancers as initially hoped. It is important therefore to consider other emerging therapeutic agents. Mutation in p53 is found in the vast majority of triple negative breast cancers, and as such is a target of particular interest. Within this review, several agents with potential activity against aberrant p53 signaling have been considered, as a novel approach to finding an effective targeted therapy for this aggressive breast cancer subtype.

Original languageEnglish
Pages (from-to)541-550
Number of pages10
JournalCancer Treatment Reviews
Volume39
Issue number5
DOIs
Publication statusPublished - Aug 2013

Fingerprint

Triple Negative Breast Neoplasms
Breast Neoplasms
Therapeutics
Progesterone
Estrogens
Clinical Trials
Drug Therapy
Mutation
Mortality

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Targeting triple negative breast cancer : Is p53 the answer? / Turner, Natalie; Moretti, Erica; Siclari, Olimpia; Migliaccio, Ilenia; Santarpia, Libero; D'Incalci, Maurizio; Piccolo, Stefano; Veronesi, Andrea; Zambelli, Alberto; Del Sal, Gianni; Di Leo, Angelo.

In: Cancer Treatment Reviews, Vol. 39, No. 5, 08.2013, p. 541-550.

Research output: Contribution to journalArticle

Turner, N, Moretti, E, Siclari, O, Migliaccio, I, Santarpia, L, D'Incalci, M, Piccolo, S, Veronesi, A, Zambelli, A, Del Sal, G & Di Leo, A 2013, 'Targeting triple negative breast cancer: Is p53 the answer?', Cancer Treatment Reviews, vol. 39, no. 5, pp. 541-550. https://doi.org/10.1016/j.ctrv.2012.12.001
Turner, Natalie ; Moretti, Erica ; Siclari, Olimpia ; Migliaccio, Ilenia ; Santarpia, Libero ; D'Incalci, Maurizio ; Piccolo, Stefano ; Veronesi, Andrea ; Zambelli, Alberto ; Del Sal, Gianni ; Di Leo, Angelo. / Targeting triple negative breast cancer : Is p53 the answer?. In: Cancer Treatment Reviews. 2013 ; Vol. 39, No. 5. pp. 541-550.
@article{b99438916c1847c992580e4a341b5d7c,
title = "Targeting triple negative breast cancer: Is p53 the answer?",
abstract = "Triple negative breast cancers, which are defined by lack of expression of estrogen, progesterone, or HER2 receptors, represent approximately 15{\%} of all breast cancers, although they account for a much higher proportional of breast cancer mortality. This is due both to their innate aggressive biological characteristics, but also to lack of effective therapies. Conventional chemotherapy is currently the only treatment option, thus there is a critical need to find new and effective targeted therapies in this disease. While investigation of agents such as poly (ADP-ribose) polymerase (PARP) inhibitors and EGFR inhibitors continues, results from recent clinical trials indicate that these therapies are not as active in sporadic triple negative breast cancers as initially hoped. It is important therefore to consider other emerging therapeutic agents. Mutation in p53 is found in the vast majority of triple negative breast cancers, and as such is a target of particular interest. Within this review, several agents with potential activity against aberrant p53 signaling have been considered, as a novel approach to finding an effective targeted therapy for this aggressive breast cancer subtype.",
author = "Natalie Turner and Erica Moretti and Olimpia Siclari and Ilenia Migliaccio and Libero Santarpia and Maurizio D'Incalci and Stefano Piccolo and Andrea Veronesi and Alberto Zambelli and {Del Sal}, Gianni and {Di Leo}, Angelo",
year = "2013",
month = "8",
doi = "10.1016/j.ctrv.2012.12.001",
language = "English",
volume = "39",
pages = "541--550",
journal = "Cancer Treatment Reviews",
issn = "0305-7372",
publisher = "W.B. Saunders Ltd",
number = "5",

}

TY - JOUR

T1 - Targeting triple negative breast cancer

T2 - Is p53 the answer?

AU - Turner, Natalie

AU - Moretti, Erica

AU - Siclari, Olimpia

AU - Migliaccio, Ilenia

AU - Santarpia, Libero

AU - D'Incalci, Maurizio

AU - Piccolo, Stefano

AU - Veronesi, Andrea

AU - Zambelli, Alberto

AU - Del Sal, Gianni

AU - Di Leo, Angelo

PY - 2013/8

Y1 - 2013/8

N2 - Triple negative breast cancers, which are defined by lack of expression of estrogen, progesterone, or HER2 receptors, represent approximately 15% of all breast cancers, although they account for a much higher proportional of breast cancer mortality. This is due both to their innate aggressive biological characteristics, but also to lack of effective therapies. Conventional chemotherapy is currently the only treatment option, thus there is a critical need to find new and effective targeted therapies in this disease. While investigation of agents such as poly (ADP-ribose) polymerase (PARP) inhibitors and EGFR inhibitors continues, results from recent clinical trials indicate that these therapies are not as active in sporadic triple negative breast cancers as initially hoped. It is important therefore to consider other emerging therapeutic agents. Mutation in p53 is found in the vast majority of triple negative breast cancers, and as such is a target of particular interest. Within this review, several agents with potential activity against aberrant p53 signaling have been considered, as a novel approach to finding an effective targeted therapy for this aggressive breast cancer subtype.

AB - Triple negative breast cancers, which are defined by lack of expression of estrogen, progesterone, or HER2 receptors, represent approximately 15% of all breast cancers, although they account for a much higher proportional of breast cancer mortality. This is due both to their innate aggressive biological characteristics, but also to lack of effective therapies. Conventional chemotherapy is currently the only treatment option, thus there is a critical need to find new and effective targeted therapies in this disease. While investigation of agents such as poly (ADP-ribose) polymerase (PARP) inhibitors and EGFR inhibitors continues, results from recent clinical trials indicate that these therapies are not as active in sporadic triple negative breast cancers as initially hoped. It is important therefore to consider other emerging therapeutic agents. Mutation in p53 is found in the vast majority of triple negative breast cancers, and as such is a target of particular interest. Within this review, several agents with potential activity against aberrant p53 signaling have been considered, as a novel approach to finding an effective targeted therapy for this aggressive breast cancer subtype.

UR - http://www.scopus.com/inward/record.url?scp=84876976694&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876976694&partnerID=8YFLogxK

U2 - 10.1016/j.ctrv.2012.12.001

DO - 10.1016/j.ctrv.2012.12.001

M3 - Article

C2 - 23321033

AN - SCOPUS:84876976694

VL - 39

SP - 541

EP - 550

JO - Cancer Treatment Reviews

JF - Cancer Treatment Reviews

SN - 0305-7372

IS - 5

ER -